Rosiglitazone accentuates the adipogenesis of hemangioma-derived mesenchymal stem cells induced by adipogenic media.

Hemangioma-derived mesenchymal stem cells (Hem-MSCs) expressed PPAR-γ, the key transcription factor in adipogenesis. We supposed that rosiglitazone, the agonist of PPAR-γ, may promote the adipogenesis of Hem-MSCs. In this study, MSCs were isolated from proliferating hemangioma. Four groups were set up, which were Group A (DMEM-LG/10% FBS), Group B (1 μM rosiglitazone + DMEM-LG/10% FBS), Group C (adipogenic media), and Group D (1 μM rosiglitazone + adipogenic media). Cells were cultured in the medium above. On the day 7 and 14, Oil Red "O" staining and Western blot were performed to detect the cytoplasmic lipid and perilipin A in the cells. The results showed that cytoplasmic lipid appeared in Group C and D, and no cytoplasmic lipid in Group A and B on the day 7 and 14. Analysis of Oil Red "O" staining showed the area of staining in Group D was significantly larger than that in Group C. Analysis of western blot showed no expression of perilipin A in Group A and B, and upregulated expression in Groups C and D, with the greater upregulation in Group D. In conclusion, our study demonstrated that rosiglitazone promoted the adipogenesis of Hem-MSCs initiated by adipogenic media via the activation of PPAR-γ pathway. The results may put forward the possibility of treating hemangioma via PPAR-γ pathway.